Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 2/20 | 0.63 |
| ▸ | DRD3 | P35462 | 1/20 | 0.61 |
| ▸ | HTR2C | P28335 | 6/20 | 0.59 |
| ▸ | PARP1 | P09874 | 1/20 | 0.56 |
| ▸ | DRD2 | P14416 | 4/20 | 0.56 |
| ▸ | HTR2A | P28223 | 1/20 | 0.55 |
| ▸ | HTR2B | P41595 | 1/20 | 0.55 |
| ▸ | DRD1 | P21728 | 3/20 | 0.52 |
| ▸ | PTPRCAP | Q14761 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29933650 | 0.82 | HTR1A (0.53) | HTR1ADRD3HTR2CPARP1DRD2 | |
| Hydrochloric Acid SCHEMBL29933648 | 0.82 | HTR1A (0.62) | HTR1ADRD3HTR2CPARP1DRD2 | |
| SCHEMBL7326109 | 0.82 | PRCP (0.50) | HTR1ADRD3HTR2CDRD2HTR2A | |
| SCHEMBL2305931 | 0.81 | PARP1 (0.63) | HTR1ADRD3HTR2CPARP1DRD2 | |
| SCHEMBL22960779 | 0.80 | DRD2 (0.70) | HTR1ADRD3HTR2CPARP1DRD2 | |
| SCHEMBL26325732 | 0.80 | DRD3 (0.78) | HTR1ADRD3HTR2CPARP1DRD2 | |
| SCHEMBL3176273 | 0.79 | HTR2C (0.63) | HTR1ADRD3HTR2CPARP1DRD2 | |
| Dopamine SCHEMBL4572712 | 0.79 | DRD3 (0.53) | HTR1ADRD3HTR2CDRD2HTR2A | |
| SCHEMBL6237859 | 0.79 | HTR2C (0.70) | HTR1ADRD3HTR2CDRD2HTR2A | |
| SCHEMBL3174699 | 0.79 | HTR2C (0.68) | HTR1ADRD3HTR2CDRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4378532-B1 | COMPOUNDS AND METHODS FOR TREATING FIBROTIC PATHOLOGIES | MAYO FOUND MEDICAL EDUCATION & RES (US) | 2025-11-12 | — | — | EP | claimed |
| US-20250179086-A1 | COMPOUNDS AND METHODS FOR TREATING FIBROTIC PATHOLOGIES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2025-06-05 | — | — | US | claimed |
| US-20240252463-A1 | METHODS OF TREATING FIBROTIC PATHOLOGIES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2024-08-01 | — | — | US | claimed |
| EP-3745862-B1 | D1 DOPAMINE RECEPTOR AGONISTS FOR TREATING FIBROTIC PATHOLOGIES | MAYO FOUND MEDICAL EDUCATION & RES (US) | 2024-06-26 | — | — | EP | claimed |
| EP-4378532-A2 | COMPOUNDS AND METHODS FOR TREATING FIBROTIC PATHOLOGIES | Mayo Foundation for Medical Education and Research (US) | 2024-06-05 | — | — | EP | claimed |
| US-20230346740-A1 | METHODS OF TREATING FIBROTIC PATHOLOGIES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2023-11-02 | — | — | US | claimed |
| EP-4003348-A1 | COMPOUNDS AND METHODS FOR TREATING FIBROTIC PATHOLOGIES | Mayo Foundation for Medical Education and Research (US) | 2022-06-01 | — | — | EP | claimed |
| WO-2004084801-A2 | TREATMENTS FOR LEISHMANIASIS | SMITHSONIAN TROPICAL RESEARCH INSTITUTE (US) | 2004-10-07 | — | — | WO | claimed |
| EP-4378532-B1 | COMPOUNDS AND METHODS FOR TREATING FIBROTIC PATHOLOGIES | MAYO FOUND MEDICAL EDUCATION & RES (US) | 2025-11-12 | — | — | EP | disclosed |
| US-20250179086-A1 | COMPOUNDS AND METHODS FOR TREATING FIBROTIC PATHOLOGIES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2025-06-05 | — | — | US | disclosed |
| US-12264163-B2 | Compounds and methods for treating fibrotic pathologies | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2025-04-01 | — | — | US | disclosed |
| US-20240252463-A1 | METHODS OF TREATING FIBROTIC PATHOLOGIES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2024-08-01 | — | — | US | disclosed |
| EP-3745862-B1 | D1 DOPAMINE RECEPTOR AGONISTS FOR TREATING FIBROTIC PATHOLOGIES | MAYO FOUND MEDICAL EDUCATION & RES (US) | 2024-06-26 | — | — | EP | disclosed |
| EP-4378532-A2 | COMPOUNDS AND METHODS FOR TREATING FIBROTIC PATHOLOGIES | Mayo Foundation for Medical Education and Research (US) | 2024-06-05 | — | — | EP | disclosed |
| WO-2004012650-A2 | COSMETIC OR DERMOPHARMACEUTICAL COMPOSITIONS CONTAINING KOMBUCHA | SEDERMA SAS (FR) | 2004-02-12 | — | — | WO | disclosed |
| WO-2002100377-A1 | PHARMACEUTICAL FORMULATION FOR THE EFFICIENT ADMINISTRATION OF APOMORPHINE, 6aR-(-)-N-PROPYL-NORAPOMORPHINE AND THEIR DERIVATIVES AND PRO-DRUGS THEREOF | AXON BIOCHEMICALS B.V (NL) | 2002-12-19 | — | — | WO | disclosed |
| WO-1999016441-A1 | APORPHINOID MATRIX METALLOPROTEINASE INHIBITORS | ROCHE DIAGNOSTICS GMBH (DE) | 1999-04-08 | — | — | WO | disclosed |
| WO-1990012574-A1 | DOPAMINE AGONIST COMPOUNDS | NORTHEASTERN UNIVERSITY (US) | 1990-11-01 | — | — | WO | disclosed |
| EP-0040074-B1 | N-SUBSTITUTED APORPHINES, A METHOD OF INDUCING EMESIS AND A METHOD OF CONTROLLING PSYCHOSIS UTILISING THE SAME | NORTHEASTERN UNIVERSITY (US) | 1985-07-31 | — | — | EP | disclosed |
| EP-0040074-A1 | N-substituted aporphines, a method of inducing emesis and a method of controlling psychosis utilising the same | NORTHEASTERN UNIVERSITY (US) | 1981-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179086-A1 | COMPOUNDS AND METHODS FOR TREATING FIBROTIC PATHOLOGIES | MMP1, MMP8, COL2A1 | HTR1A 4638/4885DRD3 4873/4885HTR2C 4757/4885 |
| US-12264163-B2 | Compounds and methods for treating fibrotic pathologies | MMP1, MMP8, COL2A1 | HTR1A 4638/4885DRD3 4873/4885HTR2C 4757/4885 |
| US-20240252463-A1 | METHODS OF TREATING FIBROTIC PATHOLOGIES | MMP1, MMP8, COL2A1 | HTR1A 4642/4885DRD3 4860/4885HTR2C 4769/4885 |
| US-20230346740-A1 | METHODS OF TREATING FIBROTIC PATHOLOGIES | MMP1, MMP8, COL2A1 | HTR1A 4642/4885DRD3 4860/4885HTR2C 4769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.